

Michael P DubÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/552827/publications.pdf>

Version: 2024-02-01

15
papers

388
citations

1040056

9
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

834
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California. <i>Journal of Viral Hepatitis</i> , 2022, , .	2.0	3
2	Sexually transmitted infections among participants in an HIV PrEP adherence trial. <i>International Journal of STD and AIDS</i> , 2022, 33, 397-403.	1.1	2
3	Gut microbiome in people living with HIV is associated with impaired thiamine and folate syntheses. <i>Microbial Pathogenesis</i> , 2021, 160, 105209.	2.9	2
4	Veillonella Bacteremia in Alcoholic Hepatitis. <i>Case Reports in Hepatology</i> , 2021, 2021, 1-4.	0.7	6
5	A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab550.	0.9	7
6	Characteristics of a cohort of high-risk men who have sex with men on pre-exposure prophylaxis reporting transgender sexual partners. <i>Medicine (United States)</i> , 2019, 98, e18232.	1.0	3
7	Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 166-174.	2.1	15
8	A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2019, 69, 1165-1172.	5.8	23
9	Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e9-e13.	2.1	33
10	Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced <i>Streptococcus</i> and increased <i>Erysipelotrichaceae</i> in rectal microbiota. <i>Scientific Reports</i> , 2018, 8, 15212.	3.3	24
11	Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2018, 218, 1551-1559.	4.0	28
12	Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1566-1572.	5.8	77
13	Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men. <i>AIDS and Behavior</i> , 2016, 20, 1173-1181.	2.7	21
14	Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1241-1249.	4.0	100
15	Lipid Metabolism in Treated HIV Infection. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 429-442.	4.7	43